|
1
|
Ferrari S, Mercuri M and Bacci G: Comment
on ‘Prognostic factors in high-grade osteosarcoma of the
extremities or trunk: An analysis of 1,702 patients treated on
neoadjuvant Cooperative Osteosarcoma Study Group protocols’. J Clin
Oncol. 20:2910–2911. 2002.PubMed/NCBI
|
|
2
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wittenburg LA, Bisson L, Rose BJ, Korch C
and Thamm DH: The histone deacetylase inhibitor valproic acid
sensitizes human and canine osteosarcoma to doxorubicin. Cancer
Chemother Pharmacol. 67:83–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koshkina NV, RaoBindal K and Kleinerman
ES: Effect of the histone deacetylase inhibitor SNDX-275 on Fas
signaling in osteosarcoma cells and the feasibility of its topical
application for the treatment of osteosarcoma lung metastases.
Cancer. 117:3457–3467. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang LP, Jin J, Lv FF, Cao J, Zhang J,
Wang BY, Shao ZM, Hu XC and Wang ZH: Norepinephrine attenuates
CXCR4 expression and the corresponding invasion of MDA-MB-231
breast cancer cells via β2-adrenergic receptors. Eur Rev Med
Pharmacol Sci. 19:1170–1181. 2015.PubMed/NCBI
|
|
8
|
Song T, Dou C, Jia Y, Tu K and Zheng X:
TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor
apoptosis by activating SDF1/CXCR4 signaling in hepatocellular
carcinoma. Oncotarget. 6:12061–12079. 2015.PubMed/NCBI
|
|
9
|
Singla AK, Downey CM, Bebb GD and Jirik
FR: Characterization of a murine model of metastatic human
non-small cell lung cancer and effect of CXCR4 inhibition on the
growth of metastases. Oncoscience. 2:263–271. 2015.PubMed/NCBI
|
|
10
|
Perissinotto E, Cavalloni G, Leone F, et
al: Involvement of chemokine receptor 4/stromal cell-derived factor
1 system during osteosarcoma tumor progression. Clin Cancer Res.
11:490–497. 2005.PubMed/NCBI
|
|
11
|
Jung Y, Wang J, Schneider A, et al:
Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible
mechanism for stem cell homing. Bone. 38:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taichman RS, Cooper C, Keller ET, Pienta
KJ, Taichman NS and McCauley LK: Use of the stromal cell-derived
factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Cancer Res. 62:1832–1837. 2002.PubMed/NCBI
|
|
13
|
Sun X, Cheng G, Hao M, et al:
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer
Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Glass DA II and Karsenty G: vivo analysis
of Wnt signaling in bone. Endocrinology. 148:2630–2634. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wodarz A and Nusse R: Mechanisms of Wnt
signaling in development. Annu Rev Cell Dev Biol. 14:59–88. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thomas DM: Wnts, bone and cancer. J
Pathol. 220:1–4. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haydon RC, Deyrup A, Ishikawa A, et al:
Cytoplasmic and/or nuclear accumulation of the beta-catenin protein
is a frequent event in human osteosarcoma. Int J Cancer.
102:338–342. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jawad MU and Scully SP: In brief:
Classifications in brief: Enneking classification: Benign and
malignant tumors of the musculoskeletal system. Clin Orthop Relat
Res. 468:2000–2002. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hoogland AM, Jenster G, van Weerden WM, et
al: ERG immunohistochemistry is not predictive for PSA recurrence,
local recurrence or overall survival after radical prostatectomy
for prostate cancer. Mod Pathol. 25:471–479. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Osborne TS and Khanna C: A review of the
association between osteosarcoma metastasis and protein
translation. J Comp Pathol. 146:132–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu WT, Bian ZY, Fan QM, Li G and Tang TT:
Human mesenchymal stem cells (hMSCs) target osteosarcoma and
promote its growth and pulmonary metastasis. Cancer Lett.
281:32–41. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nurwidya F, Takahashi F, Murakami A and
Takahashi K: Epithelial mesenchymal transition in drug resistance
and metastasis of lung cancer. Cancer Res Treat. 44:151–156. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lazennec G and Richmond A: Chemokines and
chemokine receptors: New insights into cancer-related inflammation.
Trends Mol Med. 16:133–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Balkwill F: Cancer and the chemokine
network. Nat Rev Cancer. 4:540–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kryczek I, Wei S, Keller E, Liu R and Zou
W: Stroma-derived factor (SDF-1/CXCL12) and human tumor
pathogenesis. Am J Physiol Cell Physiol. 292:C987–995. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun YX, Wang J, Shelburne CE, et al:
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers
(PCa) in vivo. J Cell Biochem. 89:462–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Müller A, Homey B, Soto H, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du YF, Shi Y, Xing YF and Zeng FQ:
Establishment of CXCR4-small interfering RNA retrovirus vector
driven by human prostate-specific antigen promoter and its
biological effects on prostate cancer in vitro and in vivo. J
Cancer Res Clin Oncol. 134:1255–1264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jeong WJ, Choi IJ, Park MW, An SY, Jeon
EH, Paik JH, Sung MW and Ahn SH: CXCR4 antagonist inhibits
perineural invasion of adenoid cystic carcinoma. J Clin Pathol.
67:992–998. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guan G, Zhang Y, Lu Y, Liu L, Shi D, Wen
Y, Yang L, Ma Q, Liu T, Zhu X, et al: The HIF-1α/CXCR4 pathway
supports hypoxia-induced metastasis of human osteosarcoma cells.
Cancer Lett. 357:254–264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang P, Dong L, Yan K, Long H, Yang TT,
Dong MQ, Zhou Y, Fan QY and Ma BA: CXCR4-mediated osteosarcoma
growth and pulmonary metastasis is promoted by mesenchymal stem
cells through VEGF. Oncol Rep. 30:1753–1761. 2013.PubMed/NCBI
|
|
32
|
Wang Z, Ma Q, Li P, Sha H, Li X and Xu J:
Aberrant expression of CXCR4 and β-catenin in pancreatic cancer.
Anticancer Res. 33:4103–4110. 2013.PubMed/NCBI
|
|
33
|
Laverdiere C, Hoang BH, Yang R, et al:
Messenger RNA expression levels of CXCR4 correlate with metastatic
behavior and outcome in patients with osteosarcoma. Clin Cancer
Res. 11:2561–2567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Libura J, Drukala J, Majka M, et al:
CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and
regulates locomotion, chemotaxis, and adhesion. Blood.
100:2597–2606. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Murakami T, Maki W, Cardones AR, et al:
Expression of CXC chemokine receptor-4 enhances the pulmonary
metastatic potential of murine B16 melanoma cells. Cancer Res.
62:7328–7334. 2002.PubMed/NCBI
|
|
36
|
Smith MC, Luker KE, Garbow JR, et al:
CXCR4 regulates growth of both primary and metastatic breast
cancer. Cancer Res. 64:8604–8612. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zlotnik A and Yoshie O: The chemokine
superfamily revisited. Immunity. 36:705–716. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Larochelle A, Krouse A, Metzger M, et al:
AMD3100 mobilizes hematopoietic stem cells with long-term
repopulating capacity in nonhuman primates. Blood. 107:3772–3778.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guergnon J and Combadière C: Role of
chemokines polymorphisms in diseases. Immunol Lett. 145:15–22.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Teicher BA and Fricker SP: CXCL12
(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Choi YH, Burdick MD, Strieter BA, Mehrad B
and Strieter RM: CXCR4, but not CXCR7, discriminates metastatic
behavior in non-small cell lung cancer cells. Mol Cancer Res.
12:38–47. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Molenaar M, van de Wetering M, Oosterwegel
M, et al: XTcf-3 transcription factor mediates β-catenin-induced
axis formation in Xenopus embryos. Cell. 86:391–399. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hsu HP, Shan YS, Jin YT, Lai MD and Lin
PW: Loss of E-cadherin and β-catenin is correlated with poor
prognosis of ampullary neoplasms. J Surg Oncol. 101:356–362.
2010.PubMed/NCBI
|
|
44
|
Wang L, Cheng H, Liu Y, et al: Prognostic
value of nuclear β-catenin overexpression at invasive front in
colorectal cancer for synchronous liver metastasis. Ann Surg Oncol.
18:1553–1559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kansara M, Tsang M, Kodjabachian L, et al:
Wnt inhibitory factor 1 is epigenetically silenced in human
osteosarcoma, and targeted disruption accelerates
osteosarcomagenesis in mice. J Clin Invest. 119:837–851. 2009.
View Article : Google Scholar : PubMed/NCBI
|
